Ascendis製藥 ASND 深 滬
等待開盤 12-15 09:30:00 美东时间
220.42
+10.260
+4.88%
華盛通- 最 高229.94
- 今 開209.41
- 成交量 146.75万股
- 最 低 207.52
- 昨 收 210.16
- 總市值 135.99亿
- 52周最高 229.94
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 118.03
- 委 比 68.95%
- 總股本 6169.52万
- 歷史最高 229.94
- 量 比 1.59
- 振 幅 10.67%
- 歷史最低 11.92
- 每 手 1
- 風險率 26.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ascendis Pharma gains amid takeover speculation
Ascendis Pharma (ASND) ADRs quickly rose 8% amid some takeover speculation. There's speculation that the Danish pharmaceutical firm may have attracted takeover interest. It's not clear who is interest...
12-13 04:24
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $256
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $254 to $256.
12-11 21:24
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.
12-09 21:16
Ascendis dwarfism drug candidate review extended by FDA
The US FDA has extended the review time of an NDA for Ascendis Pharma's (ASND) TransCon CNP (navepegritide), a treatment for children with achondroplasia. The action date is extended by three months t...
11-28 23:22
Is the Market Bullish or Bearish on Ascendis Pharma AS?
Ascendis Pharma AS's (NYSE:ASND) short interest as a percent of float has risen...
11-27 04:00
Ascendis Pharma's FDA PDUFA Date For TransCon CNP NDA Extended To February 28, 2026
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S.
11-26 07:55
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $220 Price Target
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $220 price target.
11-18 21:55
